CNS Pharmaceuticals Q3 2026 net loss narrows 22% to $2.5 million

By Public Technologies
  • CNS Pharmaceuticals’ third-quarter 2026 net loss narrowed 22% year over year to approximately $2.5 million.
  • Research and development expenses fell 59% to approximately $900,000 year over year, primarily due to lower Berubicin clinical and TPI 287 manufacturing costs.
  • General and administrative expenses rose 64% to approximately $1.8 million year over year, primarily due to higher consulting and personnel-related expenses.
  • Cash and cash equivalents more than doubled to approximately $17.2 million at September 30, 2026, compared with December 31, 2025.
  • Advanced acquisition and licensing discussions continue, with the first pipeline-building transaction targeted for completion by year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CNS Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611160730ACCESSWRNAPR_____1251586) on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.